Added to YB: 2026-04-17
Pitch date: 2026-04-15
OVID [bullish]
Ovid Therapeutics Inc.
Author Info
No bio for this author
Company Info
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.
Market Cap
$390.3M
Pitch Price
$2.80
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.83
P/E
-12.73
EV/Sales
43.20
Sector
Biotechnology
Category
growth
Ovid Therapeutics: The Master Switch
OVID: First-in-class oral KCC2 activator (OV4071) targeting upstream chloride dysregulation in schizophrenia, psychosis, epilepsy. CoM patents to 2046, no competitors. Phase 1 cleared, PoC readouts H2 2026-2027. OV329 (GABA-AT inhibitor) in drug-resistant seizures. $90M cash + $60M PIPE, runway to 2029. Stelios Papadopoulos on board signals M&A interest. Risk: CNS translation historically difficult, no human efficacy yet.
Read full article (5 min)